Our lead test candidate has completed analytical validation and is undergoing clinical validation for risk stratification and early detection of mild cognitive impairment and Alzheimer's disease. Earlier-stage programs apply the same approach to glioblastoma, neurodevelopmental disorders, and screening for other organ pathologies.